Astrocytoma, Glioma, Oligoastrocytoma, Oligodendroglioma
Conditions
Keywords
temozolomide resistant, anaplastic glioma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma
Brief summary
This is an open-label, multicenter, phase II trial, assessing the antitumor activity, and safety of temozolomide in combination with O6-BG in patients with temozolomide-resistant anaplastic glioma.
Detailed description
This open-label, multicenter, phase II trial will assess the antitumor activity and safety of temozolomide in combination with O6-BG in patients with temozolomide-resistant anaplastic glioma. Forty-one to 104 evaluable patients with temozolomide-resistant anaplastic glioma will be enrolled in this study. Total accrual on this study will not exceed 116 patients. The patients will receive daily temozolomide on 5 consecutive days (days 1-5) along with bolus infusions of O6-BG on days 1, 3, and 5 and a continuous infusion of O6-BG beginning immediately after the first bolus infusion and continuing until immediately prior to the last bolus injection. Patients will be evaluated for AEs during the course of therapy. Patients may receive treatment at the same dose level until appearance of significant treatment-related toxicities, disease progression or withdrawal of consent. Tumor response will be evaluated at the end of cycle 1, cycle 2 and then every two cycles for the duration of therapy, using physical and neurological examinations and diagnostic imaging.
Interventions
DRUGTemozolomide and O6-Benzylguanine
O6BG + Temozolomide
Sponsors
Keryx / AOI Pharmaceuticals, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with histologically documented anaplastic glioma (anaplastic astrocytoma, anaplastic oligodendroglioma or mixed anaplastic oligoastrocytoma). 2. Temozolomide-resistant defined as patients who have progressed while receiving or within 8 weeks of completing the last dose of temozolomide. 3. Disease progression \>= 12 weeks after the completion of any radiotherapy. 4. If patient received chemotherapy or an investigational agent as part of their prior therapy, the patient must recover from all toxicities (\<= Grade 1) prior to enrollment on this protocol. 5. Bi-dimensionally measurable disease on contrast-enhanced magnetic resonance imaging study (MRI) performed within two weeks of study drug administration. 6. If patient received intratumoral chemotherapy or immunotherapy as part of their prior therapy then histological confirmation of recurrence is mandated. 7. KPS \>= 70%. 8. The following laboratory results: * Absolute neutrophil count \>= 1500 cells/microliter * Platelet count \>= 100,000 cells/microliter * SGOT \<= 2.5 x ULN * Serum creatinine \<= 1.5 x ULN 9. Signed informed consent approved by Institutional Review Board. 10. If sexually active, patients will take contraceptive measures for the duration of the treatment. 11. For patients on corticosteroids, they must have been on a stable dose 1 week prior to baseline MRI and the dose should not be escalated over entry dose level, if clinically possible.
Exclusion criteria
1. Pregnant or breast feeding women. 2. Prior treatment with O6-BG plus temozolomide in combination. 3. Active infection requiring intravenous antibiotics. 4. Known diagnosis of Human Immunodeficiency Virus (HIV) infection (HIV testing is not mandatory). 5. Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention. 6. Patients unwilling or unable to comply with the protocol. 7. Patients who have received stereotactic radiosurgery or brachytherapy as part of their prior therapy. 8. Comedication that may interfere with study results; eg. immunosuppressive agents other than corticosteroids.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best objective response rate | Month 1, 2 and every 2 months thereafter. |
Secondary
| Measure | Time frame |
|---|---|
| Safety Assessment | Month 1, 2 and every 2 months thereafter |
| progression-free survival | every 6 months |
| overall survival | every 6 months |
Countries
United States
Outcome results
None listed